GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » Price-to-Free-Cash-Flow

Alector (Alector) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alector Price-to-Free-Cash-Flow?

As of today (2024-04-26), Alector's share price is $4.81. Alector's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.23. Hence, Alector's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Alector's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 8 years, Alector's highest Price-to-Free-Cash-Flow Ratio was 8.86. The lowest was 1.48. And the median was 4.53.

ALEC's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Alector's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.55. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -0.30% per year.

During the past 8 years, Alector's highest 3-Year average Free Cash Flow per Share Growth Rate was 45.80% per year. The lowest was -84.00% per year. And the median was -0.30% per year.


Alector Price-to-Free-Cash-Flow Historical Data

The historical data trend for Alector's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Price-to-Free-Cash-Flow Chart

Alector Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - 5.62 - -

Alector Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alector's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Alector's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alector's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Alector's Price-to-Free-Cash-Flow falls into.



Alector Price-to-Free-Cash-Flow Calculation

Alector's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.81/-2.228
=N/A

Alector's Share Price of today is $4.81.
Alector's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Alector  (NAS:ALEC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Alector Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Alector's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Alector (Alector) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Executives
Sara Kenkare-mitra officer: President and Head of R&D C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano officer: Chief Medical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal director, officer: Chief Executive Officer C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso officer: Chief Financial Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire director, 10 percent owner C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond director C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe director C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross director C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr director C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner director C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King officer: Chief Development Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman officer: President and COO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080